MKI67 and neoplasm: Another clinical study, D-BEYOND, which aimed to investigate whether neoadjuvant RANKL inhibition therapy can reduce tumor proliferation in premenopausal early breast cancer patients (93), found no significant change in Ki67-positive tumor cells in the breast cancer tissues treated with Denosumab, but the density of tumor-infiltrating lymphocytes (TILs) was increased in the stroma and tumor tissues upon Denosumab treatment (94).